{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T14:42:31Z","timestamp":1792334551980,"version":"4.4.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.cllc.2023.09.001","type":"journal-article","created":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T01:20:44Z","timestamp":1694913644000},"page":"689-695.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2943-3817","authenticated-orcid":false,"given":"Aakash","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash","family":"Ashara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob J.","family":"Orme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Zanwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Hocum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Nicole","family":"Moffett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna J.","family":"Schwecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Manochakian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius","family":"Ernani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panos","family":"Savvides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Dimou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushal","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9784-8603","authenticated-orcid":false,"given":"Konstantinos","family":"Leventakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2023.09.001_bib0001","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cllc.2023.09.001_bib0002","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1200\/JCO.2005.04.4859","article-title":"Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database","volume":"24","author":"Govindan","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.09.001_bib0003","doi-asserted-by":"crossref","first-page":"v710","DOI":"10.1093\/annonc\/mdz264","article-title":"IMpower133: updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo)+ carboplatin+ etoposide in extensive-stage SCLC (ES-SCLC)","volume":"30","author":"Reck","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2023.09.001_bib0005","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2023.09.001_bib0006","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S2213-2600(22)00309-5","article-title":"Combination lurbinectedin and doxorubicin versus physician\u2019s choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial","volume":"11","author":"Aix","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cllc.2023.09.001_bib0007","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non\u2013small cell lung cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.cllc.2023.09.001_bib0008","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2023.09.001_bib0009","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2023.09.001_bib0010","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.lungcan.2019.02.026","article-title":"Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line\u2013Results from the prospective German TLK cohort study","volume":"130","author":"Steffens","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2023.09.001_bib0011","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2018.11.009","article-title":"Real-world treatment patterns and outcomes of patients with small cell lung cancer progressing after 2 lines of therapy","volume":"127","author":"Coutinho","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2023.09.001_bib0012","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1111\/1759-7714.14464","article-title":"Second-line lurbinectedin as a new treatment option for small-cell lung cancer: preliminary results in real-clinical practice","volume":"13","author":"Toublanc","year":"2022","journal-title":"Thorac Cancer."},{"key":"10.1016\/j.cllc.2023.09.001_bib0013","doi-asserted-by":"crossref","first-page":"S1250","DOI":"10.1016\/j.annonc.2022.07.1633","article-title":"1539P Real-world (RW) outcomes of second-line (2L) small cell lung cancer (SCLC) patients treated with lurbinectedin","volume":"33","author":"Estrin","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2023.09.001_bib0014","series-title":"Efficacy of lurbinectedin in a Clinical Trial versus Other Standard of Care in a Real-world Comparator Arm in Relapsed\/Refractory Small Cell Lung Cancer Patients","author":"Ganti","year":"2022"},{"key":"10.1016\/j.cllc.2023.09.001_bib0015","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.lungcan.2020.10.003","article-title":"Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment","volume":"150","author":"Subbiah","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2023.09.001_bib0016","doi-asserted-by":"crossref","first-page":"15437","DOI":"10.1038\/srep15437","article-title":"Topotecan for relapsed small-cell lung cancer: systematic review and meta-analysis of 1347 patients","volume":"5","author":"Horita","year":"2015","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.cllc.2023.09.001_bib0017","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamaoncol.2022.5631","article-title":"Md. Emerging strategies for the treatment of small cell lung cancer","volume":"9","author":"Petty","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cllc.2023.09.001_bib0018","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(20)30461-7","article-title":"Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial","volume":"21","author":"Baize","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2023.09.001_bib0019","article-title":"Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer","volume":"17","author":"Pawel","year":"1999","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423001833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423001833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:15:10Z","timestamp":1761506110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730423001833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1525730423001833"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2023.09.001","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2023.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}